Cyprotex PLC Conversion of Loan Notes, Directors Dealing & TVR (5878B)
October 08 2015 - 1:00AM
UK Regulatory
TIDMCRX
RNS Number : 5878B
Cyprotex PLC
08 October 2015
Cyprotex PLC
("Cyprotex" or "the Company")
Conversion of Loan Notes, Directors Dealing
& Total Voting Rights
Cyprotex PLC (AIM: CRX), the drug discovery technology and
information company, today announces that it has issued 25,641 new
ordinary shares of 0.1p each ("new Ordinary Shares") pursuant to
the conversion of Convertible Loan Notes.
The issue of these new Ordinary shares is subject to the new
Ordinary Shares being admitted to trading on AIM, application for
which has been made. Trading in the new Ordinary Shares, which will
rank pari passu in all respects with the existing ordinary shares,
is expected to commence on 13 October 2015.
As part of this conversion the Company has received notification
that Dr. Anthony David Baxter, Chief Executive Officer of the
Company acquired 23,423 ordinary shares in the Company as a result
of conversion of Convertible Loan Notes and associated Convertible
PIK Loan Notes in the Company to the value of GBP14,054 at a
conversion price of 60 pence per share. As a result of this
conversion Dr. Baxter has a beneficial interest in 155,797 ordinary
shares in the Company representing approximately 0.69 per cent. of
the Company's total voting rights following the conversion.
Total Voting Rights
Following the issue of the 25,641 new Ordinary Shares on 13
October 2015, the Company will have a total of 22,468,340 Ordinary
Shares in issue and one voting right per Ordinary Share.
The above figure may be used by shareholders in the Company as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, the share capital of the Company under the FSA's
Disclosure and Transparency Rules.
The above information is provided by the Company in accordance
with its obligations under the FSA's Disclosure and Transparency
Rules.
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief Executive ir@cyprotex.com
Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad and broker to Tel: +44 (0)20
Cyprotex) 7496 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
About Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock
Exchange (CRX). It has sites in Macclesfield and Alderley Park,
near Manchester in the UK, Watertown, MA and Kalamazoo, MI in the
US. The Company was established in 1999 and works with more than
1100 partners within the pharmaceutical and biotech industry,
cosmetics and personal care industry and the chemical industry.
Cyprotex acquired Apredica and the assets of Cellumen Inc. in
August 2010 and the combined business provides support for a wide
range of experimental and computational ADME-Tox and PK services,
extending from early drug discovery through to IND submission. The
acquisition of the assets and business of CeeTox in January 2014
has enabled Cyprotex to expand its range of services to target the
personal care, cosmetics and chemical industries. The Company's
core capabilities include high quality in vitro ADME screening
services, mechanistic toxicology and high content toxicology
screening services, including our proprietary CellCiphr(R) toxicity
prediction technology, predictive modelling using PBPK and QSAR
techniques, including Cloe(R) PK for in vivo PK prediction, and a
range of skin, ocular and endocrine disruption services. For more
information, see www.cyprotex.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUBVVRVAARRAA
(END) Dow Jones Newswires
October 08, 2015 02:00 ET (06:00 GMT)
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2024 to May 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From May 2023 to May 2024